![Caryn Peterson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Caryn Peterson
Director/Board Member at
ASPEN NEUROSCIENCE, INC.
Net worth: 38 418 $ as of 29/09/2026
Profile
Ms. Caryn L.
Peterson is an Independent Director at Aspen Neuroscience, Inc., a Chief Development Officer at Gossamer Bio, Inc. and a Chief Executive Officer at Alevium Pharmaceuticals, Inc. She is on the Board of Directors at Aspen Neuroscience, Inc. Ms. Peterson was previously employed as a Vice President-Regulatory Affairs by OncoSec Medical, Inc., a Vice President-Regulatory Affairs by Syndax Pharmaceuticals, Inc., a Managing Partner by DSC Associates LLC, a Vice President-Regulatory Affairs by FeRx, Inc., an Associate Director-Regulatory Affairs by Amylin Pharmaceuticals, Inc., a Principal by Hybritech, Inc., and a Vice President-Regulatory Affairs by Ascenta Therapeutics, Inc.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GOSSAMER BIO, INC. 0.05% | 23/08/2026 | 3,242 ( 0.05% ) | 38 418 $ | 29/09/2026 |
| 28/10/2026 | 0 ( -.--% ) | - $ | 29/09/2026 |
Caryn Peterson active positions
| Companies | Position | Start |
|---|---|---|
| GOSSAMER BIO, INC. | Corporate Officer/Principal | - |
| ASPEN NEUROSCIENCE, INC. | Director/Board Member | 30/04/2021 |
Alevium Pharmaceuticals, Inc. | Chief Executive Officer | 31/05/2009 |
Former positions of Caryn Peterson
| Companies | Position | End |
|---|---|---|
DSC Associates LLC | Founder | 31/12/2017 |
| SYNDAX PHARMACEUTICALS, INC. | General Counsel | 31/12/2017 |
FeRx, Inc.
 FeRx, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and distributes magnetic technology for the treatment of cancer | General Counsel | 31/12/2003 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | General Counsel | 31/12/1996 |
Hybritech, Inc.
 Hybritech, Inc. Miscellaneous Commercial ServicesCommercial Services Provides prostate diagnostic testing services | Corporate Officer/Principal | 31/12/1988 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
59
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Hybritech, Inc.
Hybritech, Inc. Miscellaneous Commercial ServicesCommercial Services Provides prostate diagnostic testing services | Commercial Services |
Syndax Pharmaceuticals, Inc.
 Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
OncoSec Medical, Inc.
 OncoSec Medical, Inc. BiotechnologyHealth Technology Engages in discovery and development of novel immunotherapeutic products for immuno-oncology treatment | Health Technology |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines for cancer | Health Technology |
FeRx, Inc.
FeRx, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and distributes magnetic technology for the treatment of cancer | Health Technology |
Alevium Pharmaceuticals, Inc. | |
DSC Associates LLC | |
Gossamer Bio, Inc.
 Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Aspen Neuroscience, Inc.
 Aspen Neuroscience, Inc. BiotechnologyHealth Technology Operates as a clinical-stage regenerative medicine biotechnology company and develops autologous induced-pluripotent stem cell | Health Technology |
- Stock Market
- Insiders
- Caryn Peterson
